Pharmaceutical Calculations 13Th Edition

Total Page:16

File Type:pdf, Size:1020Kb

Load more

This page intentionally left blank. Pharmaceutical Calculations 13th Edition Pharmaceutical Calculations 13th Edition Howard C. Ansel, PhD Professor and Dean Emeritus College of Pharmacy University of Georgia Athens, Georgia Acquisitions Editor: John Goucher Managing Editor: Matt Hauber Director of Nursing Production: Helen Ewan Senior Managing Editor/Production: Erika Kors Senior Production Editor: Marian Bellus Designer: Holly McLaughlin Manufacturing Coordinator: Margie Orzech Production Services/Compositor: Maryland Composition/ASI 13th Edition Copyright ᭧ 2010 Wolters Kluwer Health ͦ Lippincott Williams & Wilkins. Copyright ᭧ 2006, 2001, 1996, 1991, 1986 by Lippincott Williams & Wilkins. All rights reserved. This book is protected by copyright. No part of this book may be reproduced or transmitted in any form or by any means, including as photocopies or scanned-in or other electronic copies, or utilized by any information storage and retrieval system without written permission from the copyright owner, except for brief quotations embodied in critical articles and reviews. Materials appearing in this book prepared by individuals as part of their official duties as U.S. government employees are not covered by the above-mentioned copyright. To request permission, please contact Lippincott Williams & Wilkins at 530 Walnut Street, Philadelphia PA 19106, via email at permissions @ lww.com or via website at lww.com (products and services). This textbook is intended to provide the underpinnings of the methods used in pharmaceutical calculations. The drugs, drug products, formulas, equations, uses, and doses are included in this textbook for the sole purpose of providing examples in the types of calculations described. The information is not intended for use in any practice or clinical application, nor should it be considered or construed as specific for any individual patient nor as a substitute for current drug package inserts. The author, editors, and publisher make no warranty, express or implied, with regard to the contents and use of this publication and are not responsible, as a matter of product liability, negligence, or otherwise, for any injury resulting from any material contained herein. 987654321 Printed in China First Edition, 1945 Library of Congress Cataloging-in-Publication Data Ansel, Howard C., 1933- Pharmaceutical calculations / Howard C. Ansel.—13th ed. p. ; cm. Includes bibliographical references and index. ISBN 978-1-58255-837-0 1. Pharmaceutical arithmetic. I. Title. [DNLM: 1. Drug Dosage Calculations. 2. Dosage Forms. 3. Drug Compounding—methods. 4. Prescriptions, Drug. 5. Weights and Measures. QV 748 A618p 2010] RS57.S86 2010 615′.1401513—dc22 2008045672 Care has been taken to confirm the accuracy of the information presented and to describe generally accepted practices. However, the authors, editors, and publisher are not responsible for errors or omissions or for any consequences from application of the information in this book and make no warranty, expressed or implied, with respect to the currency, completeness, or accuracy of the contents of the publication. Application of this information in a particular situation remains the professional responsibility of the practitioner; the clinical treatments described and recommended may not be considered absolute and universal recommendations. The authors, editors, and publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accordance with the current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new or frequently employed drug. Some drugs and medical devices presented in this publication have Food and Drug Administration (FDA) clearance for limited use in restricted research settings. It is the responsibility of the health care provider to ascertain the FDA status of each drug or device planned for use in his or her clinical practice. LWW.COM Preface The thirteenth edition of Pharmaceutical Calculations represents a thorough update of this text- book, which for more than six decades has met the needs of students in this important subject area. One of the most apparent changes in this edition is the inclusion of learning objectives for each chapter. The intent is not only to define the purpose and direct the student’s focus but also to provide a basis for self-assessment following completion. Another important addition, appearing in the Introduction, presents a step-wise approach in solving calculations problems that should prove beneficial to students toward understanding and building confidence. Throughout its history, one of the distinguishing characteristics of this textbook has been the inclusion of relevant background information to explain the pharmaceutical and/or clinical purpose underpinning each type of calculation. This practice has been continued, with new content in such areas as e-prescriptions; medication orders in nursing homes; hospice-care; patient self-administration of analgesia; intravenous infusion rate calculations for the critical care patient; patient conversions to alternative treatment plans; and other new and expanded areas. Another traditional feature of this textbook has been the substantial use of examples and practice problems. New problems have been added to reflect current drugs in use, including products of biotechnology. For the first time, several problems are presented in multiple-choice format to reflect the method of testing used in some academic programs and employed on standardized examinations. Several features that were introduced in the previous edition have been expanded, namely ‘‘Special Considerations,’’ used to point out the specific relevance of a type of calculation to a pharmaceutics or clinical application; ‘‘Calculations Capsules,’’ which present boxed summaries of the principle calculations in a chapter; and, ‘‘Case in Point,’’ which present practical case studies requiring pharmaceutical calculations. The author acknowledges the difficulty in arranging the sequence of chapters to suit the order used within each academic program. However, an attempt has been made to present a logical approach by placing the fundamentals of pharmaceutical calculations in the initial chapters, followed by chapters having a clinical- or patient-care context, then chapters that address formu- lation and compounding calculations, and, finally, chapters described by some reviewers as meeting a ‘‘special interest.’’ The concluding section of review problems contains all of the types of problems presented in the chapters and may be used both for review and for competency assessment. A new set of problems titled ‘‘Physicians’ Medication Orders’’ is introduced. Appendices include the common systems of measurement and intersystem conversion, select graphical methods, and a glossary of pharmaceutical dosage forms and associated routes of administration. v vi PREFACE New Companion Website Pharmaceutical Calculations, 13th edition, includes additional resources for both instructors and students, available on the book’s companion website at http://thePoint.lww.com/Ansel13e. Resources for Students and Instructors • Interactive math calculations Quiz Bank, with more than 400 review problems and detailed solutions. • Searchable Full Text Online See the inside front cover for more details, including the passcode you will need to gain access to the website. Acknowledgments The author gratefully acknowledges the professional contributions to his revision of pharmacy practitioner-educators Warren Beach, Ted Chaffin, Ken Duke, Elaine Lust, and Flynn Warren for lending their expertise and time. Gratitude also is extended to Loyd V. Allen Jr. and Shelly J. Prince for their continued courtesy in allowing liberal use of their work published in the International Journal of Pharmaceutical Compounding and in Pharmaceutical Calculations: The Phar- macist’s Handbook. The author thanks Barabara E. Lacher for the idea of incorporating learning objectives into the textbook and for other instructional materials. The assistance of James T. Stewart in providing access to current information from the United States Pharmacopeia 31 – National Formulary 26 is acknowledged with appreciation. Special tribute is paid to the memory of Mitchell J. Stoklosa who for more than 50 years co- authored and sustained this textbook. He was a scholar, dedicated educator, valued colleague, delightful human being, and treasured friend. Gratitude is expressed to the reviewers for this revision whose experience was drawn upon during the planning process. The author appreciates their thoughtful analysis and constructive comments, which have enhanced this work. Finally, appreciation is extended to the exceptional people at Lippincott Williams & Wilkins for their masterful job in the design, preparation, and production of this revision. Howard C. Ansel Athens, Georgia vii This page intentionally left blank. Contents Preface .................................................... v Introduction ................................................. xv Scope of Pharmaceutical Calculations ........................ xv A Step-Wise Approach Toward Pharmaceutical Calculations
Recommended publications
  • Europæisk Patentskrift

    (19) DANMARK (1°) DK/EP 2968225 T3 (12) Oversættelse af europæisk patentskrift Patent- og Varemærkestyrelsen (51) lnt.CI.: A 61 K 31/137 (2006.01) A 61 K 9/00 (2006.01) A 61 K 31/245 (2006.01) A 61 K 31/445 (2006.01) A 61 K 31/519 (2006.01) A 61 K 31/52 (2006.01) A 61 P 43/00 (2006.01) (45) Oversættelsen bekendtgjort den: 2019-05-27 (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: 2019-02-20 (86) Europæisk ansøgning nr.: 14719486.4 (86) Europæisk indleveringsdag: 2014-03-17 (87) Den europæiske ansøgnings publiceringsdag: 2016-01-20 (86) International ansøgning nr.: US2014030372 (87) Internationalt publikationsnr.: WO2014145580 (30) Prioritet: 2013-03-15 US 201361789054 P (84) Designerede stater: AL AT BE BG CH CY CZ DE DK EE ES Fl FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (73) Patenthaver: The Children's Medical Center Corporation, 55 Shattuck Street, Boston, Massachusetts 02115, USA (72) Opfinder: BERDE, Charles, 14 Doran Road, Bookline, MA 02146, USA KOHANE, Daniel S., 119 Willard Street, Newton, MA 02461, USA (74) Fuldmægtig i Danmark: AWA Denmark A/S, Strandgade 56,1401 København K, Danmark (54) Benævnelse: NEOSAXITOXINKOMBINATIONSFORMULERINGER TIL FORLÆNGET LOKALANÆSTESI (56) Fremdragne publikationer: WO-A2-98/51290 ALBERTO J. RODRIGUEZ-NAVARRO ET AL: "Potentiation of Local Anesthetic Activity of Neosaxitoxin with Bupivacaine or Epinephrine: Development of a Long-Acting Pain Blocker", NEUROTOXICITY RESEARCH, vol. 16, no. 4, 28 July 2009 (2009-07-28), pages 408-415, XP055122925, ISSN: 1029-8428, DOI: 10.1007/s12640-009- 9092-3 cited in the application Anonymous: "NCT01786655 on 2013_02_11: ClinicalTrials.gov Archive",, 11 February 2013 (2013-02-11), XP055122935, Retrieved from the Internet: URL:http://clinicaltrials.gov/archive/NCTO 1786655/2013_02_11 [retrieved on 2014-06-12] CHARLES B.
  • Local Anesthetics

    Local Anesthetics

    Local Anesthetics Introduction and History Cocaine is a naturally occurring compound indigenous to the Andes Mountains, West Indies, and Java. It was the first anesthetic to be discovered and is the only naturally occurring local anesthetic; all others are synthetically derived. Cocaine was introduced into Europe in the 1800s following its isolation from coca beans. Sigmund Freud, the noted Austrian psychoanalyst, used cocaine on his patients and became addicted through self-experimentation. In the latter half of the 1800s, interest in the drug became widespread, and many of cocaine's pharmacologic actions and adverse effects were elucidated during this time. In the 1880s, Koller introduced cocaine to the field of ophthalmology, and Hall introduced it to dentistry Overwiev Local anesthetics (LAs) are drugs that block the sensation of pain in the region where they are administered. LAs act by reversibly blocking the sodium channels of nerve fibers, thereby inhibiting the conduction of nerve impulses. Nerve fibers which carry pain sensation have the smallest diameter and are the first to be blocked by LAs. Loss of motor function and sensation of touch and pressure follow, depending on the duration of action and dose of the LA used. LAs can be infiltrated into skin/subcutaneous tissues to achieve local anesthesia or into the epidural/subarachnoid space to achieve regional anesthesia (e.g., spinal anesthesia, epidural anesthesia, etc.). Some LAs (lidocaine, prilocaine, tetracaine) are effective on topical application and are used before minor invasive procedures (venipuncture, bladder catheterization, endoscopy/laryngoscopy). LAs are divided into two groups based on their chemical structure. The amide group (lidocaine, prilocaine, mepivacaine, etc.) is safer and, hence, more commonly used in clinical practice.
  • B Pharm Syllabus

    B Pharm Syllabus

    THE TAMILNADU Dr. M.G.R. MEDICAL UNIVERSITY CHENNAI-600 032 REGULATIONS AND SYLLABUS B. PHARMACY DEGREE COURSE 2009-2010 2 THE TAMILNADU Dr. M.G.R. MEDICAL UNIVERSITY CHENNAI – 600 032 B. PHARMACY COURSE S.No. Description Page No. 1. Short Title and Commencement 5 2. Eligibility for admission 5 3. Other Criteria 6 4. National Open School Qualification 7 5. Vocational Course 7 6. Re-appearance of failed candidates 7 7. Qualification for admission into direct II year B.Pharmacy course 8 8. Age limit for admission 8 9. Physical Fitness Certificate 8 10. Eligibility Certificate 8 11. Website as Voluntary Blood Donors 8 12. Cut-off Date for Admission to Examination 9 13. Registration 9 14. Duration of the Course 9 15. Commencement of the Course 9 16. Curriculum 9 17. Medium of Instruction 9 18. Working days in the Academic Year 9 19. Attendance required for admission to examinations 9 20. Internal Assessment 10 B. Pharmacy Syllabus and2 Regulations 2009-2010 3 S.No. Description Page No. 21. Subjects of Study: 10 FIRST B.PHARM: 1. Pharmaceutical Inorganic Chemistry 21 2. Pharmaceutical Organic Chemistry 24 3. Anatomy, Physiology and Health Education 26 4. Bio-chemistry 28 5. Biostatistics and Computer Applications 30 SECOND B.PHARM: 1. Physical Pharmaceutics 32 1. Pharmaceutical Analysis and Physical Chemistry 34 3. Advanced Pharmaceutical Organic Chemistry 37 4. Pharmaceutical Technology 39 5. Pharmacy Practice and Pathophysiology 41 THIRD B.PHARM: 1. Pharmacognosy and Phyto chemistry 43 2. Medical Chemistry – I 46 3. Pharmaceutical Dosage Forms and Cosmetic Technology 50 4. Pharmacology – I 52 5.
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
  • Bachelor of Pharmacy

    Bachelor of Pharmacy

    GANDHI INSTITUTE OF TECHNOLOGY AND MANAGEMENT (GITAM) (Deemed to be University, Estd. u/s 3 of the UGC Act 1956) *VISAKHAPATNAM * HYDERABAD *BENGALURU* Accredited by NAAC with ‘A+’ Grade REGULATIONS & SYLLABUS Bachelor of Pharmacy As per the PCI Norm (w.e.f. 2018-19 admitted batch) Website: www.gitam.edu asd sfs BACHELOR OF PHARMACY (B. Pharm.) REGULATIONS as per PCI norms (w. e. f. 2018-19 admitted batch) 1. ADMISSIONS 1.1. Admissions into B. Pharm. programme of GITAM University are governed by GITAM University admission regulations. 2. ELIGIBILITY CRITERIA 2.1 A pass in 10+2 or equivalent examination approved by GITAM University with Physics, Chemistry and Mathematics/ Biology. 2.2 Admissions into B. Pharm. will be based on All India Entrance Test (GITAM Admission Test - GAT) conducted by GITAM University and the rule of reservation is followed wherever applicable. 3. DURATION OF THE PROGRAMME The course of study for B. Pharm. shall extend over a period of eight semesters (four academic years). 4. MEDIUM OF INSTRUCTION AND EXAMINATIONS Medium of instruction and examination shall be in English. 5. WORKING DAYS IN EACH SEMESTER Each semester shall consist of not less than 100 working days. The odd semesters shall be conducted from the month of June/July to November/December and the even semesters shall be conducted from November/December to April/May in every calendar year. 6. ATTENDANCE AND PROGRESS A candidate is required to put in at least 80% attendance in individual courses considering theory and practical separately. The candidate shall complete the prescribed course satisfactorily to be eligible to appear for the respective examinations.
  • (12) United States Patent (10) Patent No.: US 6,746,689 B2 Fischer Et Al

    (12) United States Patent (10) Patent No.: US 6,746,689 B2 Fischer Et Al

    USOO674.6689B2 (12) United States Patent (10) Patent No.: US 6,746,689 B2 Fischer et al. (45) Date of Patent: *Jun. 8, 2004 (54) INTRADERMAL-PENETRATION AGENTS 5,863,941 A 1/1999 Liedtke FOR TOPCAL LOCAL ANESTHETIC 5,919,479 A 7/1999 Zhang et al. ADMINISTRATION 5,922,340 A 7/1999 Berde et al. 5,955,112 A 9/1999 Kaplan (75) Inventors: Susi7- Ely. Nuits E. 6,455,0666,120,792 AB1 * 9/20029/2000 JuniFischer et al. Mason, Flemington, NJ (US) FOREIGN PATENT DOCUMENTS (73) Assignee: EpiOept Corporation, Englewood WO WO 93/12744 7/1993 Cliff. NJ (US) WO WO95/ 31.188 11/1995 s WO WO 97/439 89 11/1997 (*) Notice: Subject to any disclaimer, the term of this W W s: 2: past isis'', adjusted under 35 WO WO 01/41746 6/2001 a -- y U dayS. OTHER PUBLICATIONS This patent is Subject to a terminal dis- Berkovitch et al., 1995, “Use of a Eutectic Mixture of Local claimer. Anesthetics for Prolonged Subcutaneous Drug Administra tion”, J. Clin. Pharmacol. 35:295–297. (21) Appl. No.: 10/201,901 Curatolo, 1987, “The Lipoidal Permeability Barriers of the Skin and Alimentary Tract', Pharmaceut. Res. 4:271-277. (22) Filed: Jul. 25, 2002 Klein and Penneys, 1988, “Aloe Vera”, J. Am. Acad. Der (65) Prior Publication Data matol. 18: 714-720. Lubens et al., 1974, "Anesthetic Patch for Painful Proce US 2003/0138505 A1 Jul. 24, 2003 dures Such AS Minor Operations”, Am. J. Dis. Child. O O 128:192-194. Related U.S.
  • 3.Rohit Jaysing Bhor, Gaikwad Rohini Jagannath, C. J. Bhangale

    3.Rohit Jaysing Bhor, Gaikwad Rohini Jagannath, C. J. Bhangale

    Human Journals Review Article January 2018 Vol.:11, Issue:2 © All rights are reserved by ROHIT JAYSING BHOR et al. An Overview of "Stages of Anesthesia and Some Novel Local Anesthetics Drug” Keywords: Anesthesia; Cocaine; Benzocaine; Chloroprocaine; Procaine; Lidocaine ABSTRACT ROHIT JAYSING BHOR*1, GAIKWAD ROHINI Anesthesia means stopping of sensation and feeling. Anesthesia 2 3 JAGANNATH , C. J. BHANGALE is a state of temporary induced loss of sensation or awareness. It gives analgesia i.e. relief from pain or prevention of pain and *1Department of Pharmaceutical Chemistry, PRES’s paralysis. Local anesthesia involves injections that numb a College of Pharmacy Chincholi, Tal-Sinner, Dist-Nasik, larger or deeper part of the body. The patient stays conscious 422103, Maharashtra, India but free from pain. Local anesthetics produce anesthesia by Submission: 23 December 2017 inhibiting excitation of nerve endings or by blocking Accepted: 30 December 2017 conduction in peripheral nerves. It was achieved or done by Published: 30 January 2018 anesthetics reversibly binding to sodium channels and inactivating sodium channels. Sodium influx through these channels is necessary for the depolarization of nerve cell membranes and subsequent propagation of impulses along the course of the nerve. When a nerve loses depolarization and www.ijppr.humanjournals.com capacity to propagate an impulse, the individual loses sensation in the area supplied by the nerve. www.ijppr.humanjournals.com INTRODUCTION: Anesthesia is a state of temporary induced loss of sensation or awareness. It gives analgesia i.e. relief from pain or prevention of pain and paralysis. A patient under the effects of the anesthetic drug is known as anesthetized.
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes

    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes

    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs

    Molecules 2016, 21, 75; doi:10.3390/molecules21010075 S1 of S110 Supplementary Materials: Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs Fei Mao 1, Wei Ni 1, Xiang Xu 1, Hui Wang 1, Jing Wang 1, Min Ji 1 and Jian Li * Table S1. Common names, indications, CAS Registry Numbers and molecular formulas of 6891 approved drugs. Common Name Indication CAS Number Oral Molecular Formula Abacavir Antiviral 136470-78-5 Y C14H18N6O Abafungin Antifungal 129639-79-8 C21H22N4OS Abamectin Component B1a Anthelminithic 65195-55-3 C48H72O14 Abamectin Component B1b Anthelminithic 65195-56-4 C47H70O14 Abanoquil Adrenergic 90402-40-7 C22H25N3O4 Abaperidone Antipsychotic 183849-43-6 C25H25FN2O5 Abecarnil Anxiolytic 111841-85-1 Y C24H24N2O4 Abiraterone Antineoplastic 154229-19-3 Y C24H31NO Abitesartan Antihypertensive 137882-98-5 C26H31N5O3 Ablukast Bronchodilator 96566-25-5 C28H34O8 Abunidazole Antifungal 91017-58-2 C15H19N3O4 Acadesine Cardiotonic 2627-69-2 Y C9H14N4O5 Acamprosate Alcohol Deterrant 77337-76-9 Y C5H11NO4S Acaprazine Nootropic 55485-20-6 Y C15H21Cl2N3O Acarbose Antidiabetic 56180-94-0 Y C25H43NO18 Acebrochol Steroid 514-50-1 C29H48Br2O2 Acebutolol Antihypertensive 37517-30-9 Y C18H28N2O4 Acecainide Antiarrhythmic 32795-44-1 Y C15H23N3O2 Acecarbromal Sedative 77-66-7 Y C9H15BrN2O3 Aceclidine Cholinergic 827-61-2 C9H15NO2 Aceclofenac Antiinflammatory 89796-99-6 Y C16H13Cl2NO4 Acedapsone Antibiotic 77-46-3 C16H16N2O4S Acediasulfone Sodium Antibiotic 80-03-5 C14H14N2O4S Acedoben Nootropic 556-08-1 C9H9NO3 Acefluranol Steroid
  • Customs Tariff - Schedule

    Customs Tariff - Schedule

    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2018 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
  • Local Anesthetics

    Local Anesthetics

    Topic: LOCAL ANAESTHETICS By: [Dr. Meenaxi M. Maste] KLE College of Pharmacy, Belagavi A constituent Unit of KLE Academy of Higher Education and Research Nehru Nagar, Belagavi – 590 010, Karnataka, India Phone: 0831-2471399 Fax: 0831-2472387 Web:http://www.klepharm.eduE-mail: [email protected] LOCAL ANAESTHETICS INTRODUCTION Local anaesthetics are medications used for the purpose of temporary and reversible elimination of painful feelings in specific areas of the body by blocking transmission of nerve fibre impulses. These drugs, unlike general anaesthetics, cause a loss of feeling in specific areas while keeping the patient conscious. Local anaesthetics are used for pain relief, soreness, itching, and irritation associated with disturbance of the integrity of the skin and mucous membranes (cuts, bites, wounds, rashes, allergic conditions, fungal infections, skin sores, and cracking). They are used during opthalmological procedures such as tonometry and gonioscopy, removal of foreign bodies, and minor surgical interventions. Local anaesthetics are widely used in surgery, gynaecology, and dentistry. In certain cases, local anaesthetics (lidocaine, procainamide) can be used as anti-arrhythmic drugs. IDEAL PROPERTIES OF LOCAL ANAESTHETICS 1. Non-irritating to tissues and not causing any permanent damage 2. Low systemic toxicity 3. Effective whether injected into the tissue or applied locally to skin or mucous membranes 4. Rapid onset of anaesthesia and short duration of action MECHANISM OF ACTION A mechanism of local anaesthetic action in which they serve as sodium channel blockers has been proposed. According to this mechanism, the molecular targets of local anaesthetic action are the voltage-requiring sodium channels, which are present in all the neurons.
  • (12) United States Patent (10) Patent No.: US 7,799,337 B2 Levin (45) Date of Patent: *Sep

    (12) United States Patent (10) Patent No.: US 7,799,337 B2 Levin (45) Date of Patent: *Sep

    US0077993.37B2 (12) United States Patent (10) Patent No.: US 7,799,337 B2 Levin (45) Date of Patent: *Sep. 21, 2010 (54) METHOD FOR DIRECTED INTRANASAL (56) References Cited ADMINISTRATION OF ACOMPOSITION U.S. PATENT DOCUMENTS (76) Inventor: Bruce H. Levin, 125 Broome St., 3,105,854. A 10/1963 Druey Merion, PA (US) 19066 Continued (*) Notice: Subject to any disclaimer, the term of this ( ) patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U.S.C. 154(b) by 382 days. BE 1 OO9851. A 10, 1997 inplent is Subject to a terminal dis- (Continued) OTHER PUBLICATIONS (21) Appl. No.: 10/218,138 Goodman and Gilman's The Pharmacological Basis of Therapeutics, (22) Filed: Aug. 12, 2002 tenth edition, McGraw Hill publishing, pp. 278-281.* (65) Prior Publication Data (Continued) Primary Examiner—San-ming Hui US 2003/O133877 A1 Jul 17, 2003 y 9. ll. If, (74) Attorney, Agent, or Firm Panitch Schwarze Belisario & Related U.S. Application Data Nadel LLP (63) Continuation-in-part of application No. 09/737,302, (57) ABSTRACT filed on Dec. 15, 2000, now abandoned, and a continu riggerial o o E.2. E. Methods, kits, apparatus, and compositions for inhibiting a ation-in-part of application No. 09/118,615.filed on cerebral neurovascular disorder, a muscular headache, or Jul.17, 1998, now Pat No. 6.432.986, cerebral inflammation in a human patient are provided. The r s - 1s methods comprise intranasally administering to the patient a (60) Provisional application No. 60/117,398, filed on Jan. pharmaceutical composition comprising a local anesthetic, i.